Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04BEN
|
|||
| Former ID |
DNCL002562
|
|||
| Drug Name |
Amrubicin
|
|||
| Synonyms |
110267-81-7; Amrubicin [INN]; SCHEMBL119022; AC1L4374; (+-)-(7S,9S)-9-Acetyl-9-amino-7-((2-deoxy-beta-D-erythro-pentopyranosyl)oxy)-7,8,9,10-tetrahydro-6,11-dihydroxy-5,12-naphthacenedione; BC677604; AN-16624; LS-183761; FT-0662134; ( -)-(7S,9S)-9-Acetyl-9-amino-7-((2-deoxy-beta-D-erythro-pentopyranosyl)oxy)-7,8,9,10-tetrahydro-6,11-dihydroxy-5,12-naphthacenedione; (7S,9S)-9-acetyl-9-amino-7-(4,5-dihydroxytetrahydropyran-2-yl)oxy-6,11-dihydroxy-8,10-dihydro-7H-tetracene-5,12-dione
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Small-cell lung cancer [ICD-11: 2C25.Y; ICD-9: 162.9] | Phase 3 | [1] | |
| Company |
Celgene
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H25NO9
|
|||
| Canonical SMILES |
CC(=O)C1(CC(C2=C(C1)C(=C3C(=C2O)C(=O)C4=CC=CC=C4C3=O)O)OC5CC(C(CO5)O)O)N
|
|||
| InChI |
1S/C25H25NO9/c1-10(27)25(26)7-13-18(16(8-25)35-17-6-14(28)15(29)9-34-17)24(33)20-19(23(13)32)21(30)11-4-2-3-5-12(11)22(20)31/h2-5,14-17,28-29,32-33H,6-9,26H2,1H3/t14-,15+,16-,17-,25-/m0/s1
|
|||
| InChIKey |
VJZITPJGSQKZMX-XDPRQOKASA-N
|
|||
| CAS Number |
CAS 110267-81-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ChEBI ID |
CHEBI:135779
|
|||
| SuperDrug ATC ID |
L01DB10
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00547651) AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.